Stabilising protein therapeutics with reversible PEGylation
Researchers demonstrate the efficacy and safety of stabilising protein drugs with a reversible PEGylation material called PEG-PRX.
List view / Grid view
News
Tremfya® ranks highest for skin clearance in psoriatic arthritis patients
Newly published Network Meta-Analysis (NMA) from Janssen indirectly compares all published Phase III data for approved treatments for adults with active Psoriatic Arthritis (PsA).
Omicron prompts FDA to restrict use of specific antibodies
Based on the latest data, and Omicron's current dominance in the US, the FDA has announced two monoclonal antibody treatments are not authorised for use in any US states, territories and jurisdictions at this time.
International regulators call for multivalent COVID-19 vaccines
Regulators encourage the development of bivalent or multivalent variant COVID-19 vaccines to continue to combat the disease and its variants.
Could COVID-19 vaccines be freeze dried?
US researchers have been granted $930,000 to develop a freeze drying technique for mRNA-based COVID-19 vaccines.
Takeda and Boehringer Ingelheim named global Top Employers
Based on human resources and employee-centric practices, Takeda and Boehringer Ingelheim are among the top 11 employers worldwide.
Imfinzi™ reduces risk of death in biliary tract cancer patients
Patients treated with Imfinzi and chemotherapy experienced a 20 percent reduction in the risk of death versus chemotherapy alone.
Study finds Keytruda® improves overall survival in HCC patients
The data adds to the body of evidence relating to the use of Keytruda® as a monotherapy in second-line HCC post sorafenib.
CME to support just-in-time clinical trial supply
CME will support the delivery of automated just-in-time clinical supply, as one of the collaborators in the Medicines Manufacturing Innovation Centre Grand Challenge 2.
Riluzole not beneficial for spinocerebellar ataxia type 2
Study reveals riluzole is of no benefit in spinocerebellar ataxia type 2, emphasising the importance of studying homogeneous groups of patients.
Imfinzi™ plus tremelimumab: “unprecedented survival” in unresectable liver cancer
Almost a third of unresectable hepatocellular carcinoma patients were alive at three years on tremelimumab and Imfinzi regimen.
New FDA medical device framework to improve women’s health
The FDA’s Center for Devices and Radiological Health releases its strategic plan to improve medical device research and regulation for women.
![The GlaxoSmithKline headquarters building in Brentford, west London, June 2018 [Credit: Willy Barton / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/GSK-3-300x278.jpg)
![The GlaxoSmithKline headquarters building in Brentford, west London, June 2018 [Credit: Willy Barton / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/GSK-3-e1624534468322.jpg)
Tony Wood to replace Dr Hal Barron as GSK’s CSO
Tony Wood will assume accountability for R&D across GSK’s portfolio and pipeline from Dr Hal Barron on 1 August 2022.
mRNA COVID-19 vaccines safe for pregnant women, finds EMA review
A review of studies involving 65,000 pregnancies suggests mRNA COVID-19 vaccines do not increase the risk of pregnancy complications.
Rare Disease Clinical Outcome Assessment Consortium launched
The Rare Disease Clinical Outcome Assessment (COA) Consortium aims to advance patient-focused assessment of clinical benefit in treatment trials for rare diseases.
